Targeted Therapy in Melanoma and Mechanisms of Resistance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The BRAFV600 mutation activates the MAPK/ERK pathway, a key target in melanoma treatment.
• BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) represent a breakthrough in melanoma therapy.
• Primary and acquired resistance to BRAFi/MEKi limits treatment efficacy in 15-20% of patients.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying primary and acquired resistance to BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) in melanoma.
• To identify alternative signaling pathways involved in BRAFi/MEKi resistance.
• To provide insights for the development of novel targeted therapies overcoming treatment resistance.

Main Methods:

• Review of current literature on BRAFi/MEKi resistance mechanisms in melanoma.
• Analysis of signaling pathways implicated in resistance, including MAPK/ERK, PI3K/AKT, and receptor tyrosine kinases.
• Investigation of genetic alterations and transcriptional deregulation contributing to resistance.

Main Results:

• Resistance often involves reactivation of the MAPK/ERK pathway.
• Alternative signaling pathways such as PTEN, NF-1, RAS, PDFRβ, IGF-1R, HGF, and EGFR are frequently activated.
• Hyperactivation of tyrosine kinase receptors can lead to AKT/PI3K pathway induction.
• Deregulation of microphthalmia-associated transcription factor (MITF) is another resistance mechanism.

Conclusions:

• Understanding the diverse molecular mechanisms of BRAFi/MEKi resistance is essential for improving melanoma treatment outcomes.
• Targeting alternative signaling pathways and addressing MITF deregulation may overcome resistance.
• Further research into these pathways will guide the development of next-generation targeted therapies for resistant melanoma.